Introduction.Deep vein thrombosis and pulmonary embolism, known as venous thromboembolism, constitute a major global burden of disease. Both entities share the same risk factors. Psoriasis is a common, chronic skin disease. It also presents multisystemic inflammation, mainly affecting skin and joints, but it is also associated with the significant cardiovascular and metabolic states and comorbidities, on the so-called "psoriatic march". Case report. We presented a 78-year-old female patient, with psoriasis associated with pulmonary embolism which is accidentally discovered. We did not find any other predisposing factor of this disease (primary or secondary thrombophilia), except hyperhomocysteinemia. The patient was treated with low molecular weight heparin (enoxaparin), followed by the administration of an oral vitamin K antagonist (warfarin sodium) in the weight adjusted regimens. Additionally, we recommended vitamin B complex, including folate. Supposed link between hyperhomocysteinemia and psoriasis was the decreased serum folate level as the result of increased vitamin utilization in the skin because of increased DNA synthesis. Conclusion. The reported case reflects existing literary knowledge about the increased risk of VTE and arterial thromboembolic events in the psoriatic patients. The highest risk appears in the patients with a severe disease and may be a consequence of systemic inflammation and hyperhomocysteinemia.Uvod. Duboka venska tromboza i plućna embolija, poznate kao venski tromboembolizam (VTE), predstavljaju veliko globalno operećenje. Oba entiteta dele iste faktore rizika. Psorijaza je česta hronična bolest kože. Takođe, predstavlja multisistemsko inflamatorno oboljenje, dominantno zahvatajući kožu i zglobove koje je povezano sa značajnim kardiovaskularnim, metaboličkim stanjima i komorbiditetima, tzv. "psorijatični marš". Prikaz bolesnika. U radu prikazujemo 78-godišnju bolesnicu sa psorijazom udruženom sa plućnim embolizmom koji je slučajno otkriven. Nije utvrđen drugi predisponirajući faktor (primarna ili sekundarna trombofilija), izuzev hiperhomocisteinemije. Bolesnica je lečena niskomolekulskim heparinom (enoksafarin) i oralnim antagonistom vitamina K (varfarin natrijum), u dozama određenim prema telesnoj težini. Dodatno smo preporučili kompleks vitamina B i folate. Pretpostavljena veza između hiperhomocisteinemije i psorijaze predstavlja snižen nivo folata u serumu, kao posledica njegove povećane potrošnje u koži, zbog povećane sinteze DNK. Zaključak. Prikazani slučaj ilustruje podatke iz literature da su bolesnici sa psorijazom u povišenom riziku od venskog i arterijskog tromboembolizma. Rizik je viši kod bolesnika sa teškim oblikom bolesti, što može biti posledica sistemske inflamacije i hiperhomocisteinemije.